Sarah Davis is an Oncology physician affiliated with University of Colorado Cancer Center. OpenAlex indexes 171 publications with 1,241 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1665 Aurora Ct
University Of Colorado Cancer Center Mail Stop 703
Aurora, CO 800452517
Telephone
720-848-0300Registry record last updated 11 May 2015.
Clinical trials
- Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Sponsor: National Cancer Institute (NCI)
- Biomarkers of Immune-Related Toxicity
Sponsor: University of Colorado, Denver
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
- AstraZeneca Pharmaceuticals LPProgram year20243 payments
- TriSalus Life Sciences, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
62.9%Serotonin-3 Receptor Antagonist16%Ondansetron Hcl100%Part D≥16 patientsProton pump inhibitor14.8%Omeprazole63%Pantoprazole Sodium37%Part D<11 patients+ 4 more classes in this area
Nervous system
26.2%Opioid Agonist15.2%Oxycodone Hcl67%Morphine Sulfate Er33%Part D<11 patientsPhenothiazine6.3%Prochlorperazine Maleate100%Part D<11 patients+ 1 more class in this area
Blood & clotting
5.9%Factor Xa inhibitor5.9%Xarelto100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Antonio Jimeno, MD
University of Colorado Cancer Center
Wells Messersmith, MD
University of Colorado Cancer Center
Manali Kamdar, MD
University of Colorado Cancer Center
Richard Schulick, MD, MBA
University of Colorado Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”